Patent application number | Description | Published |
20090297454 | Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use - The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging. | 12-03-2009 |
20100248313 | NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS - The present invention relates to new optically active heteroaromatic β-hydroxy esters useful in the synthesis of epothilone derivatives, to certain compounds used to produce these intermediates, as well as to processes for their production. | 09-30-2010 |
20110130371 | C-ring-substituted pregn-4-ene-21,17-carbolactones, and pharmaceutical preparations comprising the same - The present invention relates to C-ring-substituted pregn-4-ene-21,17-carbolactones of the general formula I | 06-02-2011 |
20130252890 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND THE USE THEREOF FOR PRODUCTION OF MEDICAMENTS - The invention relates to selective oestrogen receptor modulators (SERM) and methods of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception. | 09-26-2013 |
20140194430 | SUBSTITUTED AMINOIMIDAZOPYRIDAZINES - The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 07-10-2014 |
20140288069 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES AS MKNK1 KINASE INHIBITORS - The present invention relates to amino imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said 10 compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 09-25-2014 |
20140296231 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES - The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R3 and n are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 10-02-2014 |
20140364435 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES - The present invention relates to amino-substituted imidazopyndazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 12-11-2014 |
20150038485 | HETEROCYCLYL AMINOIMIDAZOPYRIDAZINES - The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 02-05-2015 |
20150080438 | 6,7-Dihydro-5H-benzo[7]annulene derivatives, processes for their preparation, pharmaceutical products comprising them and their use for preparing medicaments - The invention relates to selective oestrogen receptor modulators (SERMs) and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception. | 03-19-2015 |
20150087631 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES - The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 03-26-2015 |
20150094300 | AMINO-SUBSTITUTED IMIDAZOPYRIDAZINES - The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I); in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 04-02-2015 |
20150274666 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFONE GROUP - The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). | 10-01-2015 |
20150274695 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP - The present invention relates to N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). | 10-01-2015 |
20150291528 | 5-FLUORO-N-(PYRIDIN-2-YL)PYRIDIN-2-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP - The present invention relates to 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). | 10-15-2015 |
20150291559 | N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP - The present invention relates to disubstituted N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I). | 10-15-2015 |
20150291599 | AMINOIMIDAZOPYRIDAZINES - The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I), in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 10-15-2015 |
20150376189 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS - The present invention relates to amido-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3, R4 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. | 12-31-2015 |
Patent application number | Description | Published |
20140339694 | Semiconductor Devices Having a Glass Substrate, and Method for Manufacturing Thereof - A method for manufacturing semiconductor devices includes providing a stack having a semiconductor wafer and a glass substrate with openings and at least one trench attached to the semiconductor wafer. The semiconductor wafer includes a plurality of semiconductor devices. The openings of the glass substrate leave respective areas of the semiconductor devices uncovered by the glass substrate and the trench connects the openings. A metal layer is formed at least on exposed walls of the trench and the openings and on the uncovered areas of the semiconductor devices of the semiconductor wafer. A metal region is formed by electroplating metal in the openings and the trench and by subsequently grinding the glass substrate to remove the trenches. The stack of the semiconductor wafer and the attached glass substrate is cut to separate the semiconductor devices. | 11-20-2014 |
20150243591 | Semiconductor Device with Plated Lead Frame, and Method for Manufacturing Thereof - A carrier substrate having a plurality of receptacles each for receiving and carrying a semiconductor chip is provided. Semiconductor chips are arranged in the receptacles, and metal is plated in the receptacles to form a metal structure on and in contact with the semiconductor chips. The carrier substrate is cut to form separate semiconductor devices. | 08-27-2015 |
20150246809 | DEVICES WITH THINNED WAFER - Methods, apparatuses and devices are described where a main wafer is irreversibly bonded to a carrier wafer and thinned to reduce a thickness of the main wafer, for example down to a thickness of 300 μm or below. | 09-03-2015 |
20150280287 | Battery, Integrated Circuit and Method of Manufacturing a Battery - A battery includes a first substrate having a first main surface, a second substrate made of a conducting material or semiconductor material, and a carrier of an insulating material. The carrier has a first and a second main surfaces, the second substrate being attached to the first main surface of the carrier. An opening is formed in the second main surface of the carrier to uncover a portion of a second main surface of the second substrate. The second main surface of the carrier is attached to the first substrate, thereby forming a cavity. The battery further includes an electrolyte disposed in the cavity. | 10-01-2015 |
20150280288 | Lithium Ion Battery, Integrated Circuit and Method of Manufacturing a Lithium Ion Battery - A lithium ion battery includes a first substrate having a first main surface, and a lid including an insulating material. The lid is attached to the first main surface of the first substrate, and a cavity is defined between the first substrate and the lid. The lithium ion battery further includes an electrical interconnection element in the lid, the electrical interconnection element providing an electrical connection between a first main surface and a second main surface of the lid. The lithium ion battery further includes an electrolyte in the cavity, an anode at the first substrate, the anode including a component made of a semiconductor material, and a cathode at the lid. | 10-01-2015 |
Patent application number | Description | Published |
20150149417 | WEB-BASED DEBUGGING OF DATABASE SESSIONS - A system includes reception, from a first user, of a first web-protocol request to establish a first database server session, establishment of the first database server session in response to the first request, reception, from a second user, of a second web-protocol request to establish a second database server session and to communicate with the second database server session via a non-transient connection, establishment of the second database server session in response to the second request, reception, from the second user, of a third web-protocol request to attach the second database server session to the first database server session, attachment of the second database server session to the first database server session, and transmission of debugging information of the first database server session to the second user via the non-transient connection. | 05-28-2015 |
20150149421 | VALIDATION OF WEB-BASED DATABASE UPDATES - A system includes reception of a request to modify the data of a database, the request including first data, execution of processing to fulfill the request, determination, during execution of the processing, that a validation exit is associated with a current state of the processing, storage of the first data in a local temporary table in response to the determination, passage of the local temporary table to the validation exit, and execution of the validation exit to validate the first data based on the local temporary table and on the data of the database. | 05-28-2015 |
20150149425 | DATABASE JOB DESCRIPTION AND SCHEDULING - A system includes acquisition of executable code of a database job, generation of a definition of the database job in a database repository, the definition of the database job comprising metadata specifying the executable code of the database job and a schedule for executing the executable code, association of a user with the database job, and activation of the database job. | 05-28-2015 |
20150149445 | ACCESSING SINGLE ENTITIES IN ODATA ENTITY SETS - A system includes activation of an OData service exposing a parameterized database view, the OData service exposing a Parameter Entity Type and a Result Entity Type, wherein the Parameter Entity Type specifies one or more input parameters of the database view as properties of the Parameter Entity Type, and defines a Parameter Entity Type key formed by each of the one or more input parameters, and wherein the Result Entity Type specifies the one or more input parameters and one or more output of the database view as properties of the Result Entity Type, and defines a Result Entity Type key formed by each of the one or more input parameters and at least one of the one or more output parameters. Also included is reception of an OData request comprising a Uniform Resource Indicator, the Uniform Resource Indicator including the OData service, the Result Entity Type, and a value for each of one or more input parameters of the database view and for at least one of the one or more output parameters of the database view, and execution, in response to the request, of the OData service to return a single entity associated with the values. | 05-28-2015 |
20150149985 | TESTING OF INACTIVE DESIGN-TIME ARTIFACTS - A system includes reception of an instruction to commit a design-time artifact of a database server application to a repository of a database server, storage of the design-time artifact in the repository of the database server in association with an inactive flag, reception of a request from a user to access the design-time artifact associated with the inactive flag, and, in response to the request, generation of a private runtime representation of the design-time artifact associated with the inactive flag, and deployment of the private runtime representation of the design-time artifact for exclusive use by the user. | 05-28-2015 |
20150150094 | SECURITY FOR DEBUGGING OF DATABASE SESSIONS - A system includes reception of authorization information associated with one or more database server sessions of a first user, the authorization information associating the first user, a second user, and an authorization period, establishment of a first database server session of the first user, establishment of a second database server session of the second user, reception, from the second user, of a request to debug the first database server session, determination, based on the authorization information, that the second user is authorized to debug the first database server session, and, in response to the determination, attachment of the second database server session to the first database server session, and transmission of debugging information of the first database server session to the second user. | 05-28-2015 |
20150150111 | SELF-SINGLE SIGN-ON - Techniques are described for providing sign-on within a trusted environment across multiple application servers. For example, a method can be provided for a single sign-on within a trusted environment across application servers. The method comprises, by a first application operating within the trusted environment, connecting to a first application server via a first access channel, and retrieving an authentication token from the first application server via the first access channel. The method further comprises, by a second application operating within the trusted environment, connecting to a second application server via a second access channel, and authenticating with the second application server with the authentication token. | 05-28-2015 |